Stavudine
- Generic Name
- Stavudine
- Brand Names
- Zerit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N2O4
- CAS Number
- 3056-17-5
- Unique Ingredient Identifier
- BO9LE4QFZF
- Background
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
- Indication
For the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Associated Therapies
- -
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Immunobiology Research Institute
- Registration Number
- NCT00002109
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Fisher Med Group, Phoenix, Arizona, United States
🇺🇸Ctr for Special Immunology, New York, New York, United States
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 55
- Registration Number
- NCT00000872
- Locations
- 🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States
🇺🇸Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00002429
- Locations
- 🇺🇸
NJCRI, Newark, New Jersey, United States
🇺🇸Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇨🇦Clinique Medicale L'Actuele, Montreal, Quebec, Canada
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00002371
- Locations
- 🇺🇸
Harbor UCLA Med Ctr, Torrance, California, United States
🇺🇸SUNY at Stony Brook / Division of Infectious Diseases, Stony Brook, New York, United States
🇨🇦Montreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada
Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Research Institute for Genetic and Human Therapy
- Target Recruit Count
- 225
- Registration Number
- NCT00002427
- Locations
- 🇺🇸
Albany Med College, Albany, New York, United States
🇺🇸Boulevard Comprehensive Care Ctr, Jacksonville, Florida, United States
🇺🇸Gary Blick MD, Stamford, Connecticut, United States
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00002376
- Locations
- 🇺🇸
Kaiser Foundation Hospital, San Francisco, California, United States
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 300
- Registration Number
- NCT00005017
- Locations
- 🇺🇸
Jaime Hernandez, Research Triangle Park, North Carolina, United States
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002227
- Locations
- 🇺🇸
The Whitman Walker Clinic, Washington, District of Columbia, United States
🇺🇸Richard Elion, Washington, District of Columbia, United States
🇺🇸Montrose Clinic, Houston, Texas, United States
A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00002162
- Locations
- 🇺🇸
UCD Med Ctr, Sacramento, California, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸UCSD Treatment Ctr, San Diego, California, United States
A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT00002184
- Locations
- 🇺🇸
Krauss Med Partners / Dept of Research and Development, Los Angeles, California, United States
🇺🇸UCLA Care Ctr, Los Angeles, California, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.